Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02411773 · ClinicalTrials.gov registry record · Phase 1
Sympatholysis in Chronic Kidney Disease
A Phase 1 study of Chronic Kidney Disease, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT02411773 is a Phase 1 study of Chronic Kidney Disease that is actively recruiting participants, run by Emory University. The registered enrollment target is 110 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02411773, a Phase 1 study of Chronic Kidney Disease, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sodium Bicarbonate
- BEHAVIORAL Exercise Training
- BEHAVIORAL Control to Exercise (Stretching)
Study Locations (1)
Georgia
- Atlanta VA Medical Center - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2015-06-11 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02411773
The ClinicalTrials.gov registry entry for NCT02411773 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (97% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02411773 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT02411773 about?
NCT02411773 is a clinical study titled "Sympatholysis in Chronic Kidney Disease". The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate).
What is the current status of trial NCT02411773?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2015-06-11. Estimated completion is 2027-06.
What conditions does trial NCT02411773 study?
This clinical trial studies the following conditions: Chronic Kidney Disease.
What interventions are being tested in trial NCT02411773?
The interventions under investigation include: Placebo (DRUG), Sodium Bicarbonate (DRUG), Exercise Training (BEHAVIORAL), Control to Exercise (Stretching) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02411773?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02411773 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
RECRUITING · Phase 1
-
Study to Assess PK, Safety and Tolerability in Patients With DM and CKD
COMPLETED · Phase 1
-
A Trial of Doxycycline in Renal Disease
COMPLETED · Phase 1
-
A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease
COMPLETED · Phase 1
-
Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.